• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Erythrityl tetranitrate; drug efficacy study implementation; revocation of exemption; opportunity for a hearing--FDA. Notice.

出版信息

Fed Regist. 1998 Jun 23;63(120):34188-90.

PMID:10180293
Abstract

The Food and Drug Administration (FDA) is revoking the temporary exemption that has allowed single-entity coronary vasodilator drug products containing erythrityl tetranitrate to remain on the market beyond the time limits scheduled for implementation of the Drug Efficacy Study. FDA is announcing that the products lack substantial evidence of effectiveness and is offering an opportunity for a hearing on a proposal to withdraw approval of any applicable new drug applications (NDA's) or abbreviated new drug applications (ANDA's).

摘要

相似文献

1
Erythrityl tetranitrate; drug efficacy study implementation; revocation of exemption; opportunity for a hearing--FDA. Notice.
Fed Regist. 1998 Jun 23;63(120):34188-90.
2
Sanofi Pharmaceuticals, Inc., et al.; withdrawal of approval of 21 new drug applications and 62 abbreviated new drug applications--FDA. Notice.赛诺菲制药公司等；21项新药申请和62项简略新药申请的批准撤回——美国食品药品监督管理局。通知。
Fed Regist. 1998 May 12;63(91):26191-3.
3
New drug applications; drug master files. Food and Drug Administration, HHS. Final rule.
Fed Regist. 2000 Jan 12;65(8):1776-80.
4
Investigational new drug applications and new drug applications--FDA. Final rule.研究性新药申请和新药申请——美国食品药品监督管理局。最终规则。
Fed Regist. 1998 Feb 11;63(28):6854-62.
5
New drugs for human use; clarification of requirements for patent holder notification--FDA. Proposed rule.供人类使用的新药；对专利持有人通知要求的澄清——美国食品药品监督管理局。拟议规则。
Fed Regist. 1998 Mar 6;63(44):11174-7.
6
Environmental assessments and findings of no significant impact--FDA. Notice.
Fed Regist. 1998 May 18;63(95):27300-3.
7
Delegations of authority and organization; Center for Drug Evaluation and Research--FDA. Final rule.授权与组织；药品评价和研究中心——美国食品药品监督管理局。最终规则。
Fed Regist. 1993 Apr 1;58(61):17093-4.
8
New drug applications and abbreviated new drug applications; technical amendment. Final rule; technical amendment.新药申请和简略新药申请；技术修订。最终规则；技术修订。
Fed Regist. 2009 Mar 6;74(43):9765-6.
9
Applications for approval to market a new drug; complete response letter; amendments to unapproved applications. Final rule.新药上市批准申请；完整回复函；未批准申请的修订。最终规则。
Fed Regist. 2008 Jul 10;73(133):39588-611.
10
Policy on 180-day marketing exclusivity for drugs marketed under abbreviated new drug applications; clarification--FDA. Clarification.关于简化新药申请下上市药品180天市场独占权的政策；澄清——美国食品药品监督管理局。澄清说明。
Fed Regist. 1997 Nov 28;62(229):63268-9.